Model-based simulation of glycaemic effect and body weight loss when switching from semaglutide or dulaglutide to once weekly tirzepatide,Current Medical Research and Opinion

当前位置： X-MOL 学术 › Curr. Med. Res. Opin. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Model-based simulation of glycaemic effect and body weight loss when switching from semaglutide or dulaglutide to once weekly tirzepatide
Current Medical Research and Opinion ( IF 2.3 ) Pub Date : 2024-03-12 , DOI: 10.1080/03007995.2024.2322072
Shweta Urva ₁ , Joshua A Levine ₁ , Karen Schneck ₁ , Cheng Cai Tang ₂

Affiliation

To evaluate the efficacy endpoints of HbA1c and body weight loss after switching from the GLP-1 receptor agonists, semaglutide or dulaglutide, to treatment with the GIP/GLP-1 receptor agonist (RA) ...

中文翻译：